Puma Biotech secures $100 million loan to market its breast cancer drug

Puma Biotechnology Inc. said it has secured a term loan of up to $100 million to market its drug Nerlynx, which was recently approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of breast cancer recurrence. Los Angeles-based Puma (Nasdaq: PBYI) said it has entered into a loan agreement with Silicon Valley Bank and Oxford Finance, a specialty finance firm that provides senior debt to life sciences and health-care services companies. Puma received gross proceeds of…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news